Info

🌱 來自：Overview-immunotherapy and cellular therapy

Ipilimumab

• Mechanism:
  • Binds to CTLA-4
• Dosing:
  • 3 mg/kg IV every 3 wks (up to 4 doses);
  • tx can be held due to ↑ liver enzymes
• PK/PD: T1/2 ∼15 d
• AEs:
  • Musculoskeletal pain,
  • fatigue,
  • rash,
  • diarrhea,
  • & immune-mediated AEs (BBW,
  • commonly includes dermatitis,
  • endocrine disorders,
  • enterocolitis,
  • hepatitis)
• DDI: No significant drug interactions
• Clinical pearls: Tx immune-related tox w/ steroids (prednisone 1-2 mg/kg/d)